GAJ - XVIII International Drug Resistance Workshop Presentations





		XVIII International HIV Drug Resistance Workshop Selected Slide Presentations Click on the links below to view presentations. Persistence, Reservoirs and Elimination Strategies Roles of NFAT, cell division and IL-7 stimulation on HIV-1 reactivation from latency in primary memory T-cells Alberto Bosque; University of Utah, USA SJ23B, a jatrophane diterpene, induces HIV receptors downregulation and HIV transcription through activation of Ras-MEK pathway and classical PKCs Jose Alcami; Instituto de Salud Carlos III, Spain Longitudinal dynamics of persistent viremia in elite controller patients versus patients on suppressive therapy Sarah Palmer; Swedish Institute for Infectious Disease Control, Karolinska Institute, Sweden HIV-specific CD4+ T-cells may contribute to viral persistence in HIV-infected elite controllers Peter Hunt; University of California, San Francisco, USA Markers of cellular immune activation do not correlate with levels of residual viremia in patients on long-term suppressive antiretroviral therapy Francesca Cossarini; National Cancer Institute, National Institutes of Health, USA No evolution of HIV-1 total DNA and 2-LTR circles after 24 weeks of raltegravir-containing regimen: a substudy of randomized EASIER-ANRS 138 trial Constance Delaugerre; Saint Louis Hospital, France Antiretroviral intensification does not reduce persistent HIV-1 viremia on therapy Frank Maldarelli; NCI Drug Resistance Program, USA Resistance to Entry Inhibitors Different mechanisms of HIV-1 inhibition by CCR5 agonists/antagonists (maraviroc, TAK-779 and PSC-RANTES) are linked to different drug resistance mechanisms Eric Arts; Case Western Reserve University, USA Estimating evolutionary pathways to CXCR4 usage from cross-sectional data Alexander Thielen; Max-Planck Institute for Informatics, Germany Modification of the CCR5 binding site by mutations in gp120 influence drug susceptibility and viral infectivity in one subject with clinical resistance to vicriviroc John Howe; Schering?Plough Research Institute, USA Resistance to Reverse Transcriptase Inhibitors: Polymerase Domain High-resolution structures of HIV-1 RT/RNA:DNA ternary complexes with tenofovir diphosphate and dATP Kalyan Das; Center for Advanced Biotechnology and Medicine (CABM), and Rutgers University, USA The HIV -1 RT mutant Q151L shows decreased replication capacity, selective high-level resistance to GS-9148 and hypersusceptibility to tenofovir and zidovudine Kirsten White; Gilead Sciences, Inc., USA Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase Matthias Götte; McGill University, Canada Different evolution and patterns of genotypic resistance profiles in emtricitabine plus tenofovir and lamivudine plus tenofovir containing regimen Valentina Svicher; University of Rome Tor Vergata, Italy Lamivudine resistance mutations in HBV reverse transcriptase can be selected even at extremely low levels of viral replication Carlo Perno; University of Rome Tor Vergata, Italy Resistance to Integrase Inhibitors New integrase binding inhibitors acting in synergy with raltegravir Laurent Thibaut; BioAlliance Pharma, France Resistance to Reverse Transcriptase Inhibitors: Connection/RNAse H Domains Mutational analysis of residue Asn348 in HIV-1 reverse transcriptase Jessica Radzio; University of Pittsburgh, USA New integrase binding inhibitors acting in synergy with raltegravir Laurent Thibaut; BioAlliance Pharma, France New integrase binding inhibitors acting in synergy with raltegravir Laurent Thibaut; BioAlliance Pharma, France Protease Inhibitor Resistance Identification of HIV-1 matrix determinants of fitness compensation in a protease inhibitor resistant virus Chris Parry; Health Protection Agency, UK Global Resistance/Epidemiology Computational models developed without a genotype for resource-poor countries predict response to HIV treatment with 82% accuracy Andrew Revell; HIV Resistance Response Database Initiative, UK Drug resistance patterns among HIV-infected children and adults failing Kaletra-based regimens in South Africa Gillian Hunt; National Institute for Communicable Diseases, South Africa Protease Inhibitor Resistance Addition of extended zidovudine to extended nevirapine prophylaxis reduces resistance in infants who were HIV-infected in utero: the PEPI-Malawi study Jessica Lidstrom; Johns Hopkins University School of Medicine, USA Pre-existing low-levels of the K103N HIV-1 RT mutation above a threshold is associated with virological failure in treatment-naive patients undergoing EFV-containing antiretroviral treatment Evguenia Svarovskaia; Gilead Sciences, Inc., USA Bulk sequence-detectable resistance mutations in peripheral RNA following single-dose nevirapine are associated with poorer treatment responses but do not adequately explain treatment failure Jeffrey Johnson; Centers for Disease Control and Prevention, USA Resistance mutations detected by oligonucleotide ligation assay of HIV-1 DNA at time of initiation of nevirapine-containing antiretroviral therapy are associated with virologic failure Thor Wagner; University of Washington and Seattle Children?s Hospital, USA State of the Art Presentation Myth Versus Reality: Preventing Drug Resistance in Resource-limited Settings Neil Parkin; World Health Organization, Switzerland